Nanocarrier vaccines for SARS-CoV-2

Jatin Machhi, Farah Shahjin, Srijanee Das, Milankumar Patel, Mai Mohamed Abdelmoaty, Jacob D. Cohen, Preet Amol Singh, Ashish Baldi, Neha Bajwa, Raj Kumar, Lalit K. Vora, Tapan A. Patel, Maxim D. Oleynikov, Dhruvkumar Soni, Pravin Yeapuri, Insiya Mukadam, Rajashree Chakraborty, Caroline G. Saksena, Jonathan Herskovitz, Mahmudul HasanDavid Oupicky, Suvarthi Das, Ryan F. Donnelly, Kenneth S. Hettie, Linda Chang, Howard E. Gendelman, Bhavesh D. Kevadiya

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

The SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death associated with substantive social, economic and societal impacts. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and the principal global effort to end the pandemic. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery.

Original languageEnglish (US)
Pages (from-to)215-239
Number of pages25
JournalAdvanced Drug Delivery Reviews
Volume171
DOIs
StatePublished - Apr 2021

Keywords

  • COVID-19 vaccine
  • Nanovaccine
  • SARS-CoV-2
  • mRNA vaccine

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Nanocarrier vaccines for SARS-CoV-2'. Together they form a unique fingerprint.

Cite this